Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Corporate venturing deal net: 9-13 December 2019
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
LeanTaas prises $40m from Goldman Sachs
NYP and Sedgwick-backed healthcare allocation software producer LeanTaas has now raised more than $100m in just over two years.
Caresyntax performs another funding operation
Mitsubishi, Barco Healthcare and Relyens helped provide $45.6m in funding for surgical analysis technology developer Caresyntax, which has now secured more than $77m altogether.
Inscripta cribs $125m in series D round
Inscripta has now accumulated more than $259m altogether from investors including Institut Mérieux, and will use the capital to further expand its genome engineering platform.
Imperative Care impresses with $79m
Ascension Ventures was among the participants in the first close of neurovascular catheter developer Imperative Care's series C round, which it expects to close at $85m. checks into first round
Ramsay Health Care was among the investors in a $19.8m first funding round for, which has already formed partnerships with Virtus Health and I-Med.
Jasper springs to life with $35m
Alexandria Venture Investments has backed a series A round for Jasper Therapeutics, which is developing a conditioning agent for patients awaiting stem cell transplants.
Akoya accepts Agilent investment to raise $50m
Agilent Technologies contributed to a $50m round for the tissue-imaging technology developer, which has earmarked the funds for product development.

Other News

Anaconda consumes $22m
Existing backer Banco Sabadell Venture Capital contributed to a round that will help the stroke surgery device developer fund clinical studies.
Ribo rips into series C1 round
Legend Capital returned as the RNA drug developer secured $28.8m in a round co-led by Panlin Capital and Trinity Innovation Fund.
Hummingbird feeds on $19m
Kooksoondang Brewery took part in a series B round for oncology antibody developer Hummingbird Bioscience as it prepares to move its lead assets into the clinic.
Kaiser Permanente Ventures caps fifth fund at $141m
Tufts Health Plan, Henry Ford Health System and Highmark Health all chipped in as care provider Kaiser Permanente's corporate VC unit closed its latest fund.
Roche polishes Black Diamond's $85m series C
The cancer drug developer emerged from stealth with $194m in funding, $85m of which was just closed in a round featuring returning investor Roche Venture Fund.
ImCheck imports $53m in series B cash
Pfizer Ventures led the immuno-oncology drug developer's latest round, which included existing backer Boehringer Ingelheim Venture Fund.

Editor's Picks

Vertex veers to Semma for $950m acquisition
Novartis, Medtronic and SinoPharm will exit the stem cell-based diabetes therapy developer in an acquisition by Vertex Pharmaceuticals.
Carroll retires from Lilly after two decades
After 22 years at Eli Lilly that included laying the groundwork for its corporate venturing activities, senior vice-president of corporate business development Darren Carroll is retiring.
BridgeBio crosses over to public markets with $349m
AIG scored an exit as genetic disease and cancer drug developer BridgeBio Pharma floated above its range while increasing the number of shares in its IPO.
test reg